Teva ($TEVA) is upping its pressure on takeover target Mylan ($MYL) as the world's largest generics maker continues its march toward turning itself into a generics colossus. This week, Teva increased its stake in Mylan, which has resisted Teva's offers. It now has control of more than 3% of Mylan's shares, giving it enough leverage to submit agenda items at a shareholder meeting next quarter, seen as pivotal in its takeover attempt. Mylan has said it doesn't think antitrust regulators would approve a merger of Teva and Mylan, but Teva claims it has explored that concern and is confident it could. More from FiercePharma